Full Press Release Details
Accessibility: Skip TopNav
Summit Corporation PLC : Director/PDMR Shareholding
June 14, 2012 09:00 ET
Summit Therapeutics plc
Summit Therapeutics plc
Summit Corporation plc
('Summit' or 'the Company')
DIRECTOR/PDMR SHAREHOLDING: PURCHASE OF SHARES
Oxford, UK, 14 June 2012, Summit (AIM: SUMM), a UK drug discovery Company announces that it has been notified that Mr George Elliott, a Non-Executive Director of the Company, today purchased 150,000 Ordinary shares of 1 pence each ("Ordinary Shares") at a price of 2.68 pence per share. Mr Elliott now holds a total of 355,291 shares.
For more information, please contact:
| Summit Glyn Edwards / Richard Pye | Tel: +44 (0)1235 443 939 |
| Singer Capital Markets (Nominated Adviser and Joint broker) Shaun Dobson / Claes Spång | Tel: +44 (0)203 205 7500 |
| Hybridan LLP (Joint broker) Claire Louise Noyce / Deepak Reddy | Tel: +44 (0)207 947 4350 |
| Peckwater PR (Financial public relations) Tarquin Edwards | Tel: +44 (0)7879 458 364 tarquin.edwards@peckwaterpr.co.uk |
Summit is an Oxford, UK based drug discovery Company with an innovative Seglin(TM) technology platform for the discovery of new medicines and a portfolio of drug programme assets. Summit's programme portfolio consists of a number of drug programmes targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection. Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com.